Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | MDH2 | P40926 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201784 | 1.00 | GABRA1 (0.35) | GABRA1GABRB2KIF11MDH2HIF1A | |
| SCHEMBL16201809 | 0.88 | KIF11 (0.34) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201814 | 0.88 | KIF11 (0.34) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201787 | 0.87 | KIF11 (0.35) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201779 | 0.87 | KIF11 (0.35) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201775 | 0.86 | KIF11 (0.39) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201778 | 0.86 | KIF11 (0.39) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201799 | 0.75 | KIF11 (0.33) | GABRA1GABRB2KIF11 | |
| SCHEMBL16201796 | 0.75 | KIF11 (0.33) | GABRA1GABRB2KIF11 | |
| SCHEMBL19733885 | 0.71 | KIF11 (0.40) | GABRA1GABRB2KIF11ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323457-A1 | BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS | Technische Universität München (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323457-A1 | BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS | FASN, DEGS1, EBP | GABRA1 673/4885GABRB2 377/4885KIF11 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.